The flumatinib you are talking about is the second generation. Since it is the second generation, it naturally means better. It can suppress the disease deeper and more stably, and the test indicators drop faster and lower. In terms of safety, skin toxicity and gastrointestinal reactions were more common in the flumatinib group. Common adverse events were diarrhea. There were no cardiac and cardiovascular system adverse reactions. The incidence of edema was lower than that of Gleevec. It can be seen that flumatinib is an updated product of Gleevec, and it is an innovative drug originally developed in China. For young people like your brother, the future is still long. The ideal thing is to be able to stop the drug, and the second-generation drug can be stopped. The drug potential is much higher than that of the first-generation drugs, and the quality of life is also higher, so flumatinib can be used.